$RLYB News

Last published 1d ago

1d agoRLYBCorrection to Press Release Announcing Reverse Stock Split of Rallybio Common Stock in Connection with the Proposed Merger with AvenzoBusiness WireEAST BERLIN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced a correction to its press release issued November 10, 2026. The prior press release incorrectly stated that the one-for-two reverse stock split of Rallybio’s issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of ...
2d agoRLYBRallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with AvenzoBusiness WireEAST BERLIN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued and outstanding common stock in connection with the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated as of May 31, 2026, among Rallybio, Avenzo Therapeutics, Inc. (“Avenzo”) and Farmington Merger Sub, Inc ...
6d agoRLYBTrading halt: Rallybio Corp Cmn Stk (RLYB), News pendingNasdaq Trading HaltsHalted 2026-11-06 17:44:05.880 ET, resumption quote none, resumption trade none.
5mo agoRLYBRallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private PlacementBusiness WireCombined company to operate as Avenzo Therapeutics, advancing a leading portfolio of next-generation oncology therapies, including small molecules and antibody-drug conjugates Concurrent oversubscribed private
8mo agoRLYBRallybio Corporation and Candid Therapeutics Announce Merger AgreementBusiness WireCombined company to operate as Candid Therapeutics, advancing a leading portfolio of T-cell engager therapeutics for autoimmune diseases Concurrent significantly oversubscribed and upsized financing of over $505
8mo agoRLYBRallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal ComplementBusiness Wire– Data Support the Study of RLYB116 as a Potential Best-In-Class Therapeutic for Multiple Complement Mediated Diseases – – Initiation of RLYB116 Phase 2 Clinical Trial in Immune Platelet Transfusion Refractoriness
9mo agoRLYBRallybio Announces Reverse Stock Split of Common StockBusiness WireRallybio Corporation (NASDAQ:RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio's Amended and Restated
1y agoRLYBRallybio Reports Third Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire– RLYB116 Confirmatory PK/PD Study Data Expected in 4Q 2025 – – Generated $20 Million from Sale of Interest in REV102 – – Cash Runway Extended through 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage
1y agoRLYBRallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyBusiness Wire– Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic and Enable Progression to Cohort 2 –
1y agoRLYBRallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 ProgramBusiness Wire– Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia – – Extends Cash Runway through 2027 – Rallybio
1y agoRLYBRallybio Reports Second Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire– Data Readouts from Cohort 1 and Cohort 2 of RLYB116 Confirmatory PK/PD Study on Track for 3Q and 4Q 2025, Respectively – – Sold Interest in REV102 to Recursion Pharmaceuticals for Up to $25 Million, including an
1y agoRLYB RXRXRecursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for HypophosphatasiaGlobeNewswireSalt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio's
1y agoRLYBRallybio Sells Interest in REV102 Program to Recursion PharmaceuticalsBusiness Wire– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology
1y agoRLYBRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic StudyBusiness Wire– Potential to Address a Broad Range of Complement-Mediated Diseases with Initial Focus on Immune Platelet Transfusion Refractoriness and Refractory Antiphospholipid Syndrome – – Data Readouts Expected from Cohort 1
1y agoRLYBRallybio Reports First Quarter 2025 Financial Results and Provides Business UpdatesBusiness Wire– On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31,
1y agoRLYBRallybio to Present at the 2025 Citizens JMP Life Sciences ConferenceBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden,
1y agoRLYBRallybio to Discontinue Development of RLYB212 for Prevention of FNAITBusiness Wire– RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025
1y agoRLYBRallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesBusiness Wire— Key Data Readouts from Sentinel Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 and 3Q 2025 — — Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025
1y agoRLYBRallybio to Present at the TD Cowen 45th Annual Health Care ConferenceBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden,
1y agoRLYBRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical TrialBusiness Wire– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies
1y agoRLYBRallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025Business Wire– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 – – Initiation of RLYB116 Confirmatory PK/PD Study Expected in 2Q 2025, with Data Anticipated in 2H 2025 – – REV102, an
1y agoRLYBRallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual MeetingBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of
1y agoRLYBRallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025Business Wire-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study – -- Manufacturing Process Enhancements Expected to Further Improve
1y agoRLYBRallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant WomenBusiness Wire— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative
1y agoRLYBRallybio to Present at the 2024 Evercore ISI HealthCONx ConferenceBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden,
1y agoRLYBRallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 InhibitorBusiness Wire-- Webcast to be held on Monday, December 2, 2024 at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for
1y agoRLYBRallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212Business Wire— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances
2y agoRLYBRallybio Reports Third Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire— CTA Approvals Received for RLYB212 Phase 2 Clinical Trial; On Track to Initiate Screening in 4Q 2024 — — $75.1 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2024 Provides Runway
2y agoRLYBRallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAITBusiness Wire— First Ever Trial in Pregnant Women at Higher Risk of Alloimmunization and FNAIT — — Screening in the Phase 2 Clinical Trial On Track to Initiate in 4Q 2024 — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage
2y agoEXAI RLYBData Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual MeetingBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that nonclinical data
2y agoRLYBRallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual MeetingBusiness Wire– Results Indicate that FNAIT Risk is More Prevalent Than Previously Estimated – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies
2y agoRLYBRallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough SummitBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from
2y agoRLYBFierce Names Rallybio to the 2024 Fierce 50 List as an Innovation HonoreeBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that Fierce Life
2y agoRLYBRallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and HaemostasisBusiness Wire– Study Demonstrates that RLYB212 Rapidly Clears HPA-1a Positive Platelets, an Essential Step in Preventing Alloimmunization and FNAIT – – Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in
2y agoRLYBRallybio to Present at Upcoming Investor ConferencesBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in
2y agoRLYBRallybio Reports Second Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire– On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 4Q 2024 – – $88.6 Million in Cash, Cash Equivalents, and Marketable Securities as of June 30, 2024 Provides
2y agoRLYBRallybio to Present at the 2024 Jones Healthcare Seaside SummitBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Jonathan Lieber,
2y agoRLYBRallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse PopulationsBusiness Wire– First Reported Large-Scale Analysis of FNAIT Risk Across Broad Population of Diverse Ancestries – – Topline Results Suggest a Significant Increase in the Number of Pregnancies at Higher Risk for FNAIT Annually and
2y agoRLYBRallybio Reports First Quarter 2024 Financial Results and Provides Business UpdatesBusiness Wire- On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 - - $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides
2y agoRLYBRallybio to Present at the 2024 Citizens JMP Life Sciences ConferenceBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today
2y agoRLYBFNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual MeetingBusiness Wire- Data Support HPA-1a Negative Frequency of More than 2% in Nearly 200,000 Screened Pregnant Women - - Among HPA-1a Negative Pregnant Women, Approximately 33% are at Higher Risk for Alloimmunization - Rallybio
2y agoRLYBRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)Business Wire- Rallybio to Receive Funding for FNAIT Awareness Initiative and Equity Investment from Johnson & Johnson - Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and
2y agoRLYBRallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual MeetingBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today
2y agoRLYBRallybio Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire-- Received Protocol Assistance Feedback from European Medicines Agency on the Phase 2 Study for RLYB212; Company to Proceed Forward with Clinical Trial Application Process in Europe -- -- Phase 2 Dose Confirmation
2y agoRLYBRallybio to Present at the TD Cowen 44th Annual Health Care ConferenceBusiness WireRallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today
2y agoRLYBRallybio Announces Portfolio Prioritization and Provides Corporate UpdateBusiness Wire– Prioritization of Phase 2-ready clinical-stage programs: RLYB212 for the prevention of FNAIT and RLYB116, a C5 inhibitor for the treatment of patients with complement-mediated diseases – – Anticipated cost savings,
2y agoRLYBRallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024Business Wire-- Phase 2 Study for RLYB212 Expected to Initiate in 2H 2024 -- -- Company to Provide Update on Phase 2 Discussions with European Medicines Agency for RLYB212 in 1H 2024 -- -- Cash Runway Extended into 3Q 2025
2y agoRLYBRallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5Business Wire-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment
2y agoRLYBRallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual MeetingBusiness Wire-- FNAIT Natural History Study to Inform Frequency of FNAIT Risk in a Broad and Diverse Population of Pregnant Women -- -- Study Designed to Provide a Contemporary Control Dataset to Support a Future Registrational
2y agoRLYBRallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune ThrombocytopeniaBusiness Wire-- Preliminary Data Support RLYB212 Once Monthly Subcutaneous Dosing in Phase 2 Study -- -- RLYB212 Toxicology Package Complete, Including Maternal-Fetal Toxicology; Key Activity to Support Phase 2 and Phase 3 Studies